Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza

Vaccine. 2010 Aug 23;28(37):5952-9. doi: 10.1016/j.vaccine.2010.07.003. Epub 2010 Jul 8.

Abstract

Employers may be loath to fund vaccination programs without understanding the economic consequences. We developed a decision analytic computational simulation model including dynamic transmission elements that estimated the cost-benefit of employer-sponsored workplace vaccination from the employer's perspective. Implementing such programs was relatively inexpensive (<$35/vaccinated employee) and, in many cases, cost saving across diverse occupational groups in all seasonal influenza scenarios. Such programs were cost-saving for a 20% serologic attack rate pandemic scenario (range: -$15 to -$995) per vaccinated employee) and a 30% serologic attack rate pandemic scenario (range: -$39 to -$1,494 per vaccinated employee) across all age and major occupational groups.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Computer Simulation
  • Cost-Benefit Analysis
  • Decision Making
  • Disease Outbreaks / prevention & control*
  • Humans
  • Influenza Vaccines / economics*
  • Influenza, Human / epidemiology
  • Influenza, Human / prevention & control*
  • Models, Economic*
  • Vaccination / economics*
  • Workplace

Substances

  • Influenza Vaccines